Testosterone, DHT, Body Hair, Beard Growth, and Male Pattern Baldness: The Androgen Paradox

The relationship between androgens and hair is paradoxical: the same hormonal environment that drives beard and body hair development also causes progressive miniaturization of scalp follicles in male pattern baldness. The hormone is the same; the follicle response is opposite depending on location.

This resolves the apparent contradiction between "high testosterone = more beard" and "high testosterone = faster hair loss."

The DHT Mechanism

Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, which is expressed in hair follicles. DHT has approximately 3–5x greater binding affinity for the androgen receptor than testosterone and is more potent in driving androgen-sensitive responses.

Body hair and beard follicles: Androgen receptors in these follicles respond to DHT by extending the anagen (growth) phase and increasing follicle size. DHT promotes hair growth at these locations.

Scalp follicles (in genetically susceptible men): Scalp follicles in men carrying the genetics for androgenetic alopecia respond to DHT in the opposite direction — progressive follicle miniaturization. The anagen phase shortens, the telogen (resting/shedding) phase extends, and the follicle produces progressively finer, shorter hairs until it becomes non-functional.

The genetic susceptibility involves androgen receptor gene variants on the X chromosome associated with differential DHT sensitivity. This is why male pattern baldness is partially linked to the maternal grandfather — a popular but oversimplified observation; multiple genes contribute.

> 📌 Ellis et al. (2002) confirmed that androgen receptor density in hair follicles differs between balding and non-balding scalp areas within the same individuals — balding follicles show significantly higher receptor density, which explains the location-specific response to an identical androgen environment. [1]

5-Alpha Reductase Inhibitors

This mechanism is the basis for pharmaceutical treatment of male pattern baldness.

Finasteride (1mg, Propecia): Inhibits 5-alpha reductase type II, reducing scalp DHT concentration by approximately 60–70%. Roughly 60–70% of men taking finasteride show no further hair loss; a subset show regrowth. Side effects in approximately 2–3%: sexual dysfunction (libido changes, erectile dysfunction), typically reversible on cessation. Persistent sexual side effects following cessation — "post-finasteride syndrome" — are reported, but prevalence remains debated.

Minoxidil: Works by a different mechanism — vasodilation of scalp blood vessels and anagen phase extension through pathways that aren't fully characterised. Effective in approximately 60% of users; requires continued use to maintain effect.

Does Testosterone Level Predict Baldness?

No — not reliably. Baldness is a function of DHT sensitivity at the follicle level, determined primarily by genetics: androgen receptor density and type. Men with relatively low testosterone can develop severe baldness; men with high testosterone can retain full hair. The determinant is how the follicle responds to whatever DHT is present, not the total circulating androgen level.

---